Postablation signs predict successful lung RFA

Article

A lesion’s contrast enhancement pattern and change in size after treatment can predict the successful radio-frequency ablation of a lung tumor, according to a study in the October issue of the American Journal of Roentgenology.

A lesion's contrast enhancement pattern and change in size after treatment can predict the successful radio-frequency ablation of a lung tumor, according to a study in the October issue of the American Journal of Roentgenology.

Dr. Gong Yong Jin and colleagues at Chonbuk and Seoul National University Hospitals in Korea retrospectively evaluated 21 patients who underwent percutaneous RFA for lung cancer and metastases from extrapulmonary lesions. Using contrast-enhanced CT, they sought to describe postablation lesion characteristics and patient response to treatment.

The researchers found that the most successfully ablated lesions appeared on follow-up scans as low-attenuation areas without contrast enhancement. These lesions consistently shrank on subsequent follow-up scans.

Based on contrast-enhanced CT findings after treatment, the researchers split patients into two groups: those who had achieved complete ablation, and those with a partial ablation. Follow-up CT imaging of each group showed serial changes in enhancement patterns, size, peripheral ground-glass opacities, and other factors.

Nine patients in the complete ablation group showed no contrast enhancement on follow-up CT. Their lesions' mean reduction rate at three, six, nine, 12, and 15 months compared with the size right after treatment was 5.7%, 11.4%, 14.3%, 40%, and 40%, respectively.

Twelve patients in the partial ablation group showed diverse degrees of enhancement. In contrast to the previous group, their lesions gradually increased in size after the six-month follow-up with CT. Five out of 21 lesions on postablation scans showed enveloped ground-glass opacity surrounding the tumor.

Usually, a brief increase in blood flow occurs along the tissue surrounding an ablated lesion. Experts speculate that residual malignant cells overlapping this area might go undetected by follow-up CT immediately after treatment. Ablation should thus include a peripheral normal tissue margin of .5 to 1 cm to boost results and increase the sensitivity of treatment follow-up.

Lack of histopathologic confirmation limited the study's measure for success. Several other researchers, however, agree that contrast-enhanced CT findings may correlate well with the ablated lesion's pathologic features, the investigators wrote in the study.

For more information from the Diagnostic Imaging archives:

Lung RFA moves up a notch

RFA for liver breaks further ground

RF ablation of lung tumors wins support

RF tumor ablation breaks through in clinical practice

Recent Videos
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Related Content
© 2025 MJH Life Sciences

All rights reserved.